Clinical trials: Rectum Neoplasms
Colorectal Neoplasms, Adenocarcinoma of the Colon
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
This study, for patients who have Stage IIIC colorectal cancer and who underwent 5-fluorouracil/leucovorin with oxaliplatin (FOLFOX) chemotherapy after surgery, will test to see if regorafenib given after the completion of FOLFOX…
- Conditions
- Colorectal Neoplasms, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT02425683
- Testing
- Regorafenib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- US Oncology Research
Colorectal Neoplasm, Iron Deficiency Anemia
Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
The main objective of this study is to evaluate the efficacy of intravenous iron sucrose in increasing preoperative haemoglobin values in patients with colo-rectal neoplasm and iron deficiency anemia, compared to the standard…
- Trial name
- NCT00199277
- Testing
- i.v. iron sucrose, Oral iron
- Where
- 5 sites in Spain
- Volunteers
- 150 people
- Sponsor
- J. Uriach and Company
Rectal Cancer
Pre-op Rectal ChemoRad +/- Cetuximab
The purpose of this research study is to find out what effects (good and bad) cetuximab has on rectal cancer.
- Trial name
- NCT00527111
- Testing
- Cetuximab, 5-fluorouracil, Pelvic irradiation
- Where
- 41 sites in United States
- Volunteers
- 139 people
- Sponsor
- US Oncology Research
Colorectal Carcinoma
A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B)
The primary objective of this study is to investigate the safety and tolerability of the anti-vascular endothelial growth factor receptor-2 (anti-VEGFR-2) monoclonal antibody Ramucirumab (IMC-1121B) in combination with…
- Trial name
- NCT01286818
- Testing
- Ramucirumab (IMC-1121B), Irinotecan, levofolinate
- Where
- 3 sites in Japan
- Volunteers
- 6 people
- Sponsor
- Eli Lilly and Company
Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer
xDRIVE in Metastatic Colorectal Cancer
The study aims to evaluate the clinical utility of the xDRIVE functional precision medicine + artificial intelligence (AI) platform in predicting treatment response for metastatic colorectal cancer (mCRC).
- Conditions
- Metastatic Colon Adenocarcinoma, Metastatic Colon Cancer, Metastatic Rectal Adenocarcinoma, Metastatic Rectal Carcinoma
- Trial name
- NCT06929338
- Testing
- Functional precision medicine
- Sponsor
- First Ascent Biomedical Inc.
Colorectal Cancer, Colon Cancer
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
- Conditions
- Colorectal Cancer, Colon Cancer, Rectal Cancer, Colorectal Neoplasms
- Trial name
- NCT00041652
- Testing
- hMN14 (labetuzumab)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Gilead Sciences
Cancer
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00101972
- Testing
- monoclonal antibody RAV12
- Where
- 5 sites in United States
- Volunteers
- 53 people
- Sponsor
- MacroGenics
Advanced Solid Tumor, Anal Cancer
Phase 1 Study of Oral TP-1454
This study will evaluate the safety and tolerability of oral TP-1454 in patients with advanced metastatic or progressive solid tumors and anal cancer.
- Trial name
- NCT04328740
- Testing
- TP-1454 monotherapy
- Where
- 11 sites in United States
- Volunteers
- 31 people
- Sponsor
- Sumitomo Pharma America, Inc.
Genital Wart, Penile Cancer
A Phase III Study to Evaluate the Efficacy, Immunogenicity and Safety of the 9-valent HPV Vaccine in Chinese Males
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 9-valent (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Human Papillomavirus (HPV) Recombinant Vaccine (Hansenula Polymorpha) in Chinese male…
- Conditions
- Genital Wart, Penile Cancer, Anal Cancer, PIN-1
- Trial name
- NCT06465914
- Testing
- 9-valent Human Papillomavirus (Types 6, 11, 16, 18, 31, 33, 45, 52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- Where
- 5 sites in China
- Volunteers
- 9,000 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Rectal Cancer
Taking a Look at Patient Experiences In Rectal Cancer Clinical Trials
The primary objective of this research study is to explore the barriers encountered by specific demographic groups of rectal cancer patients during the engagement in clinical trials, which historically lack diverse…
- Trial name
- NCT05910099
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Metastatic Colorectal Cancer, Colon Cancer
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT01605318
- Testing
- Labetuzumab Govitecan (LG)
- Where
- 7 sites in United States
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
Rectal Cancer
A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer
The purpose of this study is to determine the pathological complete tumor response rate.
- Trial name
- NCT02694718
- Testing
- Capecitabine, Oxaliplatin
- Where
- 6 sites in Switzerland
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Left-sided Colorectal Resection : Diverticular Diseases, Left-sided Colorectal Resection : Colonic Neoplasms
InTRaoperative Imaging DEvice Based on endogeNous opTical Properties to Evaluate Bowel Oxygenation in Colorectal Resections
The objective of the study is to assess the safety and technical feasibility of a new imaging system, used during colorectal resection surgery, named Trident in version 1.0, which could be used by the surgeon during colorectal…
- Conditions
- Left-sided Colorectal Resection : Diverticular Diseases, Left-sided Colorectal Resection : Colonic Neoplasms, Left-sided Colorectal Resection : Rectal Neoplasms
- Trial name
- TRIDENT (NCT05973227)
- Testing
- use of the TRIDENT system
- Where
- France
- Volunteers
- 10 people
- Sponsor
- Intuitive Surgical
Solid Tumor, Colorectal Cancer
Live Biotherapeutic Product GB104 Phase 1 Study in Colorectal Cancer
Prospective, open label, multi-dose, sequential dose escalation, single-center, Phase 1 trial
- Conditions
- Solid Tumor, Colorectal Cancer, Sigmoid Colon Cancer, Rectosigmoid Junction Cancer
- Trial name
- NCT05943041
- Testing
- GB104(Level 1), GB104(Level 2), GB104(Level 3)
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- GILongevity
Carcinoma, Pancreatic Ductal, Colorectal Neoplasms
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
The purpose of this study is to learn about the safety and effects of the study medicine alone or when given together with other anti-cancer therapies. This study also aims to find the best dose.
- Conditions
- Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT06447662
- Testing
- PF-07934040, Gemcitabine, Nab-paclitaxel
- Where
- 27 sites in United States, Puerto Rico
- Volunteers
- 64 people
- Sponsor
- Pfizer
Colorectal Neoplasms
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
The purpose of this study is to determine whether CPX-1 is effective in patients with advanced colorectal cancer who have already received chemotherapy that included the drug oxaliplatin or irinotecan.
- Trial name
- NCT00361842
- Testing
- CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
- Where
- 13 sites in United States, Canada
- Volunteers
- 65 people
- Sponsor
- Jazz Pharmaceuticals
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
Metastatic Colorectal Cancer, Colon Cancer
Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
This phase 1/2, multi-center, randomized, double-blind, placebo-controlled trial is designed to evaluate the efficacy and safety of AMG 655 when combined with mFOLFOX6 and bevacizumab compared with mFOLFOX6 and bevacizumab alone…
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
- Trial name
- NCT00625651
- Testing
- AMG 655, Modified FOLFOX6, Bevacizumab
- Where
- 61 sites in United States
- Volunteers
- 202 people
- Sponsor
- Amgen
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.